NASDAQ:GERN 12 December 2025

Geron (NASDAQ:GERN) rises as Rytelo sales move guidance midpoint within range

Shares of Geron rose on Wednesday, as Rytelo sales continued to climb for another quarter. At the current rate, second-quarter sales would annualize at $229.9 million, aligning closely with the midpoint of Geron's 2026 revenue forecast.

5 August 2026

Earnings·NASDAQ:GERN·Pharmaceuticals·Stock Market

Geron Stock (NASDAQ: GERN) News Today: Restructuring, Analyst Ratings, and 2026 Catalysts (Dec. 12, 2025)

Geron Corporation stock is back in focus on December 12, 2025, as investors digest a sweeping restructuring tied to the company’s commercial push for RYTELO and its longer-term clinical ambitions. The headlines have been loud—one-third of the workforce is set to be cut, analysts are re-checking their models, and the market is weighing a familiar biotech question: is this the start of a leaner turnaround, or a sign that growth has stalled? Geron Corporation+2BioPharma Dive+2

12 December 2025

Biotechnology·NASDAQ:GERN·Stock Market